GOLDMAN SACHS GROUP INC - FIVE PRIME THERAPEUTICS INC ownership

FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 131 filers reported holding FIVE PRIME THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.88 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of FIVE PRIME THERAPEUTICS INC
ValueSharesWeighting
Q1 2021$54,053,000
+1046.4%
1,434,903
+417.7%
0.01%
+1200.0%
Q4 2020$4,715,000
+539.8%
277,161
+76.6%
0.00%
Q3 2020$737,000
-26.9%
156,899
-5.0%
0.00%
Q2 2020$1,008,000
+800.0%
165,213
+234.1%
0.00%
Q1 2020$112,000
-72.0%
49,446
-43.2%
0.00%
Q4 2019$400,000
+20.1%
87,092
+1.3%
0.00%
Q3 2019$333,000
-78.0%
86,009
-65.7%
0.00%
Q2 2019$1,514,000
-12.2%
251,084
+95.1%
0.00%
-100.0%
Q1 2019$1,725,000
+43.4%
128,724
-0.4%
0.00%
Q4 2018$1,203,000
-56.5%
129,270
-35.0%
0.00%
-100.0%
Q3 2018$2,766,000
-8.0%
198,741
+4.5%
0.00%0.0%
Q2 2018$3,007,000
-32.7%
190,172
-26.9%
0.00%0.0%
Q1 2018$4,469,000
+11.2%
260,175
+41.9%
0.00%0.0%
Q4 2017$4,018,000
+57.2%
183,300
+193.3%
0.00%0.0%
Q3 2017$2,556,000
-58.9%
62,490
-69.8%
0.00%
-50.0%
Q2 2017$6,221,000
-20.9%
206,598
-5.0%
0.00%0.0%
Q1 2017$7,861,000
+74.8%
217,462
+142.2%
0.00%
+100.0%
Q4 2016$4,498,000
-86.9%
89,769
-86.3%
0.00%
-90.0%
Q3 2016$34,347,000
+296.2%
654,352
+212.1%
0.01%
+400.0%
Q2 2016$8,669,000
-1.6%
209,641
-3.3%
0.00%
-33.3%
Q1 2016$8,812,000
+18.1%
216,860
+20.6%
0.00%
+50.0%
Q4 2015$7,464,000
+1207.2%
179,838
+384.5%
0.00%
Q3 2015$571,000
-47.4%
37,119
-15.1%
0.00%
Q2 2015$1,085,000
+136.4%
43,699
+117.7%
0.00%
Q1 2015$459,000
+61.6%
20,069
+90.8%
0.00%
Q4 2014$284,000
-94.9%
10,520
-97.8%
0.00%
-100.0%
Q3 2014$5,564,000
-29.4%
474,372
-6.4%
0.00%0.0%
Q2 2014$7,881,000
-20.4%
506,789
+0.7%
0.00%
-33.3%
Q1 2014$9,895,000
+23.0%
503,292
+5.1%
0.00%0.0%
Q4 2013$8,042,000478,9660.00%
Other shareholders

There were no reported owners of FIVE PRIME THERAPEUTICS INC in Q4 2020.

NameSharesValueWeighting ↓
View complete list of FIVE PRIME THERAPEUTICS INC shareholders